VBI: Encouraging Early Glioblastoma Tumor Response Data From Phase 2b

 

• Data highlighted in oral presentation at World Vaccine Congress 2024 on April 3, 2024
• Early data from patients eligible for evaluation at week 12 show two observations of stable disease, indicating no tumor progression, in VBI-1901 treatment arm (n=2/5; 40% disease control rate [DCR])
• By comparison, no tumor responses have been observed in the control arm to-date (n=0/6; 0% DCR), with all patients seeing a 2-8x increase in tumor size by week 6
• FDA has granted both Fast Track Designation and Orphan Drug Designation to VBI-1901 in recurrent GBM following encouraging Phase 1/2a study results
• Additional interim data expected mid-year and year-end 2024

https://www.biospace.com/article/releases/vbi-vaccines-presents-encouraging-early-tumor-response-data-from-randomized-controlled-phase-2b-study-of-vbi-1901-in-recurrent-glioblastoma/